GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » LT-Debt-to-Total-Asset

CTNM (Contineum Therapeutics) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Contineum Therapeutics's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.00.

Contineum Therapeutics's long-term debt to total assets ratio increased from Jun. 2023 (0.00) to Jun. 2024 (0.00). It may suggest that Contineum Therapeutics is progressively becoming more dependent on debt to grow their business.

Contineum Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Contineum Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics LT-Debt-to-Total-Asset Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
0.05 0.02 -

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only - - - - -

Contineum Therapeutics LT-Debt-to-Total-Asset Calculation

Contineum Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0.108/130.386
=0.00

Contineum Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )/Total Assets (Q: Jun. 2024 )
=0.113/221.355
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Contineum Therapeutics  (NAS:CTNM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Contineum Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Website
https://www.contineum-tx.com
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024